NCT02545829View on ClinicalTrials.gov

Evaluating the Bioequivalence of HIP1302, HGP1406

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

HIP1302

Tenofovir 292mg

DRUG

HGP1406

Tenofovir 300mg

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02545829 - Evaluating the Bioequivalence of HIP1302, HGP1406 | Biotech Hunter | Biotech Hunter